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Randomized Comparison of Percutaneous Coronary
Intervention With Sirolimus-Eluting Stents
Versus Coronary Artery Bypass Grafting in
Unprotected Left Main Stem Stenosis
Enno Boudriot, MD,* Holger Thiele, MD,* Thomas Walther, MD,† Christoph Liebetrau, MD,*
Peter Boeckstegers, MD,‡ Tilmann Pohl, MD,‡ Bruno Reichart, MD,§ Harald Mudra, MD,
Florian Beier, MD, Brigitte Gansera, MD,¶ Franz-Josef Neumann, MD,# Michael Gick, MD,#
Thomas Zietak, MD,** Steffen Desch, MD,* Gerhard Schuler, MD,* Friedrich-Wilhelm Mohr, MD†
Leipzig, Munich, and Bad Krozingen, Germany
Objectives The purpose of this randomized study was to compare sirolimus-eluting stenting with coronary artery bypass
grafting (CABG) for patients with unprotected left main (ULM) coronary artery disease.
Background CABG is considered the standard of care for treatment of ULM. Improvements in percutaneous coronary inter-
vention (PCI) with use of drug-eluting stents might lead to similar results. The effectiveness of drug-eluting stent-
ing versus surgery has not been established in a randomized trial.
Methods In this prospective, multicenter, randomized trial, 201 patients with ULM disease were randomly assigned to
undergo sirolimus-eluting stenting (n  100) or CABG using predominantly arterial grafts (n  101). The primary
clinical end point was noninferiority in freedom from major adverse cardiac events, such as cardiac death, myo-
cardial infarction, and the need for target vessel revascularization within 12 months.
Results The combined primary end point was reached in 13.9% of patients after surgery, as opposed to 19.0% after PCI
(p  0.19 for noninferiority). The combined rates for death and myocardial infarction were comparable (surgery,
7.9% vs. stenting, 5.0%; noninferiority p  0.001), but stenting was inferior to surgery for repeat revasculariza-
tion (5.9% vs. 14.0%; noninferiority p  0.35). Perioperative complications including 2 strokes were higher after
surgery (4% vs. 30%; p  0.001). Freedom from angina was similar between groups (p  0.33).
Conclusions In patients with ULM stenosis, PCI with sirolimus-eluting stents is inferior to CABG at 12-month follow-up with
respect to freedom from major adverse cardiac events, which is mainly influenced by repeated revascularization,
whereas for hard end points, PCI results are favorable. A longer follow-up is warranted. (Percutaneous Coronary
Intervention [PCI] With Drug-Eluting Stents [DES] Versus Coronary Artery Bypass Graft [CABG] for Patients With
Significant Left Main Stenosis; NCT00176397) (J Am Coll Cardiol 2011;57:538–45) © 2011 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.09.038S
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ccepted September 2, 2010.ignificant stenosis of the unprotected left main stem (ULM)
as a worse prognosis than any other form of coronary artery
isease (1). Coronary artery bypass grafting (CABG) is con-
idered the standard of care for ULM as surgery provides a
urvival benefit in comparison to medical therapy (1–4).
See page 546
Concern about procedural risk, unpredictable occurrence
f abrupt closure, restenosis, and long-term results led to
uideline recommendations that percutaneous coronary in-
ervention (PCI) be restricted to poor surgical candidates or
ypass-protected ULM (5,6).
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February 1, 2011:538–45 Stenting Versus Surgery in Left Main DiseaseThe advent of coronary stents along with the evolution of
ual antiplatelet therapy dramatically lowered the incidence
f abrupt vessel closure, and the application of drug-eluting
tents further decreased the risk of in-stent restenosis (7).
herefore, PCI is increasingly used to treat ULM lesions (8).
Limited evidence, mainly from registries (9,10), suba-
alyses of the Synergy Between PCI With Taxus and
ardiac Surgery (SYNTAX) trial (11), and 1 small random-
zed trial (12), led to the recent updated recommendation
hat PCI may be considered an alternative to surgery in
atients with anatomic low-risk conditions and clinical high
isk of adverse events with surgery (13).
The current multicenter, randomized study was con-
ucted to assess whether sirolimus-eluting stenting is non-
nferior in comparison to CABG using predominantly
rterial grafts among patients with ULM stenoses at 12-
onth follow-up.
ethods
atients age 18 to 80 years with stenosis (50%) of the
LM with or without additional multivessel coronary artery
isease were included in this multicenter study. Patients had
o be symptomatic or have documented myocardial ischemia.
Exclusion criteria were myocardial infarction 48 h
equiring immediate intervention, additional valvular heart
isease requiring surgery, previous surgical treatment for
oronary artery or valvular disease, severe peripheral arterial
isease, significant carotid stenosis requiring treatment,
enal dysfunction requiring dialysis, any disease with limited
ife expectancy, overt congestive heart failure, and contrain-
ication to antiplatelet therapy. Angiographic exclusion
riteria were total occlusions, extreme left-dominant coro-
ary artery perfusion, and distal lesion length 30 mm in a
ingle lesion.
A consensus on patient eligibility had to be obtained from
oth a cardiac surgeon and cardiologist (E.B.) prior to
andomization. Patients not eligible were also analyzed for
linical events at 12-month follow-up in a prospective
egistry.
The SYNTAX score and the logistic European system
or cardiac operative risk evaluation (EuroSCORE) were
omputed for risk analysis by a cardiologist blinded to
rocedural data and clinical outcome (14,15).
The study was approved by the local ethics committee of
he participating centers. Written informed consent was
btained from all patients. Balanced randomization was
erformed by a computerized randomization program at an
ndependent institution. Stratification was performed ac-
ording to centers.
CI. PCI was performed using the femoral approach in all
atients. Sirolimus-eluting stents were used in all except
patients, who required a stent diameter 4 mm and
herefore received paclitaxel-eluting stents. Direct stenting
f the ULM was the preferred strategy except for cases with
ritical luminal narrowing, for which pre-dilation was per- normed. Lesions in the ostium or
ody of the ULM usually re-
eived a single stent. On the basis
f anatomic findings, distal
LM stenoses were treated by
everal techniques (16). Post-
ilation with kissing balloon an-
ioplasty was always used to fin-
sh the distal stenting procedure.
dditional stenting of lesions
istal to the ULM was per-
ormed according to standard clinical practice with the aim
f complete revascularization. There was no recommenda-
ion to use intravascular ultrasound routinely.
Antiplatelet therapy was started the day before PCI with
spirin (at least 100 mg orally, followed by 100 mg or more
er day indefinitely post-procedure) and clopidogrel (600
g orally, followed by 75 mg/day for at least 12 months).
dditional glycoprotein IIb/IIIa inhibitor use was left to the
iscretion of the operator.
ABG. Standard CABG surgery was performed under
eneral anesthesia using a conventional sternotomy ap-
roach. Complete revascularization using arterial grafts was
ecommended. Off-pump techniques were used at the
iscretion of the surgeon. Antiplatelet therapy consisted of
spirin 100 mg per day preoperatively and was continued
ndefinitely post-operatively.
Other pharmacological treatments such as statins,
ngiotensin-converting enzyme inhibitors, and beta-
lockers were recommended based on current practice in
oth treatment groups.
For both groups, complete revascularization was defined
s bypass grafting or PCI of all lesions with 50% stenosis
n vessels with a diameter of 2.0 mm.
ollow-up. All patients were closely monitored for at least
4 h post-procedure. Creatine kinase and MB activity was
easured immediately after the procedure and 8, 16, and
4 h later. A 12-lead electrocardiogram was obtained
mmediately post-procedure and at 24 h.
Post-hospital follow-up included a 6-month outpatient
isit with a clinical examination and a symptom-limited
xercise stress test. The 12-month follow-up included a
ymptom-limited exercise stress test and coronary angiog-
aphy. Restenosis was defined as50% diameter stenosis by
isual assessment. In case of recurrence of angina and/or a
ositive stress test, repeat revascularization was performed
or restenosis. A final clinical follow-up by structured
elephone interview was performed in November 2009,
nsuring a longer follow-up.
nd points and definitions. The primary composite end
oint was defined as freedom from major adverse cardio-
ascular events, which included death from any cause,
yocardial infarction, and the need for repeat revascular-
zation within 12 months.
Secondary end points included each individual compo-
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
IQR  interquartile range
PCI  percutaneous
coronary intervention
ULM  unprotected left
mainent of the composite end point. The clinical angina status
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Stenting Versus Surgery in Left Main Disease February 1, 2011:538–45as assessed according to the Canadian Cardiovascular
ociety classification. In addition, periprocedural adverse
vents were documented.
Myocardial infarction was defined as an increase in
reatine kinase-MB activity 3 times the upper limit of
ormal after PCI and 5 times after CABG (17). In
ddition, standard electrocardiographic criteria were ap-
lied. The incidence of stent thrombosis was evaluated in
ccordance with the Academic Research Consortium defi-
itions (17). Repeat revascularization was defined as any
evascularization by CABG or PCI within 12 months, and
as subdivided into target lesion revascularization of the
LM and distally located lesions or those of the right
oronary artery.
Recorded periprocedural events were: 1) low cardiac
utput syndrome requiring intravenous inotropic agents
nd/or intra-aortic balloon counterpulsation; 2) congestive
eart failure requiring hospital readmission; 3) cerebrovas-
ular events (stroke, coma, transient ischemic attack, or
rolonged ischemic neurological deficit); 4) pericardial tam-
onade; 5) arrhythmia (ventricular fibrillation, ventricular
achycardia, or new atrial fibrillation) requiring treatment;
) major bleeding requiring additional blood transfusion;
) resternotomy for bleeding; 8) renal insufficiency requiring
ialysis; 9) major infections compromising post-procedural
ehabilitation; 10) vascular access site complications requir-
ng surgical intervention; and 11) sternum instability or
nfection requiring additional treatment.
All clinical outcomes were adjudicated by a clinical event
ommittee consisting of a cardiothoracic surgeon and a
ardiologist blinded to treatment allocation.
tatistical analysis. The objective was to determine
hether PCI with sirolimus-eluting stents was not inferior
o the currently accepted standard of CABG surgery. It was
ssumed that 15% of the patients treated by surgery and
2.5% treated by PCI would reach the combined primary
nd point at 12 months. A sample size of 100 from surgery
nd 100 from stenting achieved 80% power at a 5%
ignificance level using a 1-sided equivalence test at the
aximum allowable difference of 10% between the groups.
his difference has been used previously and is very similar
o the 9% rate for the left main subgroup in the SYNTAX
rial (11,18).
All analyses were conducted according to the intention-
o-treat principle. Patients lost to follow-up were included
ntil the last contact. One-sided significance tests of non-
nferiority and exact 95% confidence intervals were com-
uted for the differences in event rates between the random-
zed groups using procedures implemented in StatXact
Cytel Inc., Cytel Studio 8.0, Cambridge, Massachusetts) (19).
Despite not being powered for the analysis of individual
nd points of the combined end point, noninferiority
argins were analyzed to allow hypothesis generation.
Data for categorical variables are expressed as number and
ercentage of patients. Most continuous variables had non-
ormal distribution and are therefore presented as medians Pogether with interquartile range (IQR). Continuous values
ere compared by unpaired Student t tests after testing for
ormal distribution, or Wilcoxon rank sum test when
ppropriate. Fisher exact test or chi-square tests were used
or categorical variables. For long-term clinical end points,
he Kaplan-Meier method was applied and differences
ssessed by the log-rank test. All statistical tests were
erformed with SPSS software, version 17.0 (SPSS Inc.,
hicago, Illinois). A 2-tailed p value 0.05 was considered
tatistically significant. By protocol, there were no interim
nalyses.
esults
rom July 2003 to February 2009, a total of 430 patients
ith ULM disease at 4 tertiary care centers were screened
or inclusion into the trial. Of these, 201 patients met the
nclusion criteria and were randomly assigned to PCI (n 
00) or CABG (n  101). The remaining 229 patients
ntered the prospective registry (Fig. 1). Reasons for non-
nclusion in the randomized trial are listed in Figure 1.
Comparison of pre-procedural variables for the 2 ran-
omized groups showed no significant differences (Table 1).
he average interval between randomization and treatment
as 1.0 days (IQR: 1.0 to 3.0 days) for patients assigned
o PCI and 4.0 days (IQR: 2.0 to 7.0 days) for surgery
p  0.001).
rocedural outcomes. All patients received the assigned
reatment. However, 3 patients randomized to PCI had to
e converted to CABG, without any subsequent complica-
ions. In 2 of these, the high-grade stenosis of ULM
ifurcation could be crossed with a wire that extended only
nto the left circumflex artery; however, the left anterior
escending coronary artery could not be wired. Another
atient had a subtotal mid-left anterior descending artery
tenosis that could not be recanalized; because complete
evascularization was mandatory by trial protocol, conversion
o CABG was indicated. A median of 2.0 (IQR: 1.0 to 4.0)
irolimus-eluting stents were implanted using a median
mplantation pressure of 16.0 atms (IQR: 14.0 to 18.0 atms).
he median total stent length was 36.0 mm (IQR: 18.0 to
9.0 mm) (Table 2).
CABG was successfully performed in all patients ran-
omized to surgery, with a median of 2.0 (IQR: 2.0 to 3.0)
rafts and a total of 254 distal anastomoses. Nearly one-half
f the patients (46%) were operated on using an off-pump
“beating heart”) technique. In all patients, the left internal
ammary artery was used to bypass the left anterior
escending coronary artery, except for 1 who had a non-
atent left internal mammary artery. Additionally, 37 pa-
ients received radial arterial and 55 right internal mammary
rtery grafts. Altogether, 35 patients (35%) received 1 or
ore saphenous vein graft distal anastomoses. Total arterial
evascularization was achieved in 66 patients (65%) (Table
). The rates of complete revascularization were 98% in the
CI and 97% in the CABG groups.
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February 1, 2011:538–45 Stenting Versus Surgery in Left Main DiseasePeriprocedural adverse events were rare after PCI, with 1
pisode of acute renal failure (1%) and 3 episodes of atrial
brillation (3%) in comparison to CABG (2 strokes [2%]; 1
ritical illness neuropathy and persistent incomplete tetra-
Figure 1 Trial Profile Showing the Number of Screened, Random
The reasons for noninclusion in the randomized trial are shown for registry patient
and secondary end point analysis in the randomized trial is shown. CABG  coron
Patient CharacteristicsTable 1 Patient Characteristics
Variable PCI (n 
Age, yrs 66 (62–
Men 72 (72)
Body mass index, kg/m2 27.2 (24.
Cardiovascular risk factors
Current smoking 35 (35)
Hypertension 82 (82)
Hypercholesterolemia 68 (68)
Diabetes mellitus 40 (40)
Previous myocardial infarction 19 (19)
Q-wave infarction 17 (17)
Non–Q-wave infarction 2 (2)
Previous stroke 3 (3)
Baseline creatinine, mol/l* 86.0 (76.
Left ventricular ejection fraction, % 65.0 (55.
Logistic EuroSCORE 2.4 (1.5
Discharge medication
Aspirin 100 (100
Clopidogrel 100 (100
Beta-blocker 99 (99)
ACE inhibitor/AT-1 antagonist 98 (98)
Statins 97 (97)
Values are given as median (IQR) or n (%). *To convert mol/l to mg/
ACE  angiotensin-converting enzyme; AT-1  angiotensin receptor type 1
PCI  percutaneous coronary intervention.legia [1%]; 19 new atrial fibrillation/flutter episodes requir-
ng treatment [19%]; 2 resternotomy for bleeding with
dditional blood transfusion [2%]; 1 renal insufficiency
equiring dialysis [1%]; and 5 major infections compromis-
, and Registry Patients
itionally, the number of patients at follow-up for primary
ery bypass grafting; PCI  percutaneous coronary intervention.
) CABG (n  101) p Value
69 (63–73) 0.24
78 (77) 0.49
) 27.0 (24.9–30.1) 0.31
28 (28) 0.34
83 (82) 0.88
65 (64) 0.89
33 (33) 0.35
14 (14) 0.43
10 (10)
4 (4)
6 (6) 0.51
.0) 86.0 (75.0–97.0) 0.52
) 65.0 (55.0–68.0) 0.88
2.6 (1.7–4.9) 0.08
101 (100) 0.99
32 (32) 0.001
96 (95) 0.22
93 (92) 0.11
95 (94) 0.51
tiply serum creatinine values by 0.0113.ized
s. Add
ary art100
73)
6–31.5
5–100
0–70.0
–3.7)
)
)
dl, mul
; CABG  coronary artery bypass grafting; IQR  interquartile range;
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Stenting Versus Surgery in Left Main Disease February 1, 2011:538–45ng post-procedural rehabilitation [5%]). In total, 4 PCI
atients (4%) had a periprocedural event in comparison to
0 CABG patients (30%) (p  0.001).
The median total hospital days in the stenting group were
.0 days (IQR: 2.0 to 4.0 days) and 13.0 days (IQR: 11.0 to
4.0 days) in the surgery group (p 0.001), and the median
ospital stay after revascularization was 1.0 days (IQR: 1.0
o 1.5 days) versus 8.0 days (IQR: 7.0 to 9.0 days) (p 
.001).
ngiographic follow-up. Angiographic follow-up was not
ompleted in 5 PCI (5%) and 20 CABG (20%) patients
p  0.001) (Fig. 1). A significant target lesion restenosis
ccurred in 9 PCI patients (9%). Restenoses of the target
esion were usually focal, and all occurred in patients with
istal ULM disease. Furthermore, 5 de novo stenoses in the
CI group were treated interventionally. There were no
tent thromboses in the PCI group. After CABG, 25
Angiographic CharacteristicsTable 2 Angiographic Characteristics
Variable PCI (n 
Lesion type
Ostial 20 (20)
Trunk 6 (6)
Distal 74 (74)
Isolated left main 28 (28)
Left main  1-vessel disease 35 (35)
Left main  2-vessel disease 26 (26)
Left main  3-vessel disease 11 (11)
PCI technique for distal left main
T-stenting 40 (40)
Provisional T-stenting 30 (30)
Crush-stenting 3 (3)
V-stenting 1 (1)
CABG, conduits per patient
Left internal mammary artery —
Right internal mammary artery —
Radial artery —
Venous graft —
SYNTAX score (15) 24.0 (19.0
Values are given as n (%) or median (IQR).
SYNTAX  Synergy Between PCI With Taxus and Cardiac Surgery; o
Major Adverse Cardiac Events at 12-Month Foll(in Descending Order of S verity) According t ITable 3 Majo Advers Cardiac Events a 12(in Descending Order of Severity) A
PCI
(n  100)
Death 2 (2.0)
Myocardial infarction 3 (3.0)
30 days 3 (3.0)
Day 30 to 12 months —
Myocardial infarction  death 5 (5.0)
Repeat revascularization 14 (14.0)
30 days 1 (1.0)
Day 30 to 12 months 13 (13.0)
Any major adverse cardiac event 19 (19.0)Values are given as n (%).
CI  confidence interval; other abbreviations as in Table 1.nastomoses (n  10 left internal mammary artery, n  7
ight internal mammary artery, n  5 radial artery, n  3
enous grafts) in 21 patients (21%) were totally occluded or
ad relevant stenosis of 50%. Most of these were asymp-
omatic. A new relevant stenosis in a native coronary was
etected in 2 patients (2%).
ollow-up. At 12-month follow-up, the combined clinical
nd point was reached in 19.0% of patients after PCI and in
3.9% after CABG (Table 3). The difference in the event
ates was 5.1% and did not satisfy the statistical criteria for
oninferiority (upper bound 10.0%, p  0.19 for nonin-
eriority). Individual components of the combined end point
evealed mixed results. Whereas noninferiority was con-
rmed for the difference in death and myocardial infarction,
oninferiority was not established for the difference in
epeat revascularization (Table 3). A total of 10 (10.0%)
arget lesion and 4 (4.0%) de novo artery stenosis revascu-
CABG (n  101) p Value
0.72
23 (23)
8 (8)
70 (69)
29 (29) 0.49
27 (27)
28 (28)
17 (17)
—
—
—
—
100 (99)
55 (54)
37 (37)
35 (35)
) 23.0 (14.8–28.0) 0.09
breviations as in Table 1.
tion-to-Treat Analysisth F llow-Up
ing to Intention-to-Treat Analysis
CABG
 101)
95% CI for
Differences
p Value
Noninferiority
5 (5.0) 9.4 to 2.7 0.001
3 (3.0) 5.8 to 5.9 0.002
3 (3.0) 5.8 to 5.9 0.002
— 3.7 to 3.7 0.001
8 (7.9) 10.6 to 4.4 0.001
6 (5.9) 0.3 to 17.1 0.35
2 (2.0) 6.1 to 3.7 0.001
4 (4.0) 1.3 to 17.6 0.45
4 (13.9) 5.3 to 15.7 0.19100)
–29.0ow-Upnten-Mon
ccord
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February 1, 2011:538–45 Stenting Versus Surgery in Left Main Diseasearizations occurred in the PCI group, compared with 6
5.9%) repeat revascularizations after CABG. The majority
f revascularizations were treated by PCI (83.0%). Of note,
he incidence of major adverse cardiac events in ostial/shaft
esions was 1.0% versus 18.0% in distal left main lesions for
he PCI group and 5.0% versus 8.9% for CABG patients.
ombined rates of death, infarction, and stroke were 5.0%
n the PCI versus 8.9% in the CABG group.
At longer follow-up of 36.5 months (IQR: 24.4 to 60.9
onths), the results were similar for the combined clinical
nd point (Fig. 2A) and for the differences in death and
yocardial infarction (Fig. 2B), as well as for repeat
evascularization (Fig. 2C).
Noneligible patients in the registry had higher major
dverse cardiac event rates at 12-month follow-up (PCI
7.5%, CABG 17.8%, conservative therapy 43.0%). Mor-
ality at 1 year was 12.5% after PCI, 12.8% after CABG,
nd 33.1% after conservative therapy; the repeat revascular-
zation rate was 20.9% after PCI and 4.5% after CABG.
nly 1 myocardial infarction occurred post-procedure, in a
atient who underwent CABG surgery.
linical symptoms and physical work capacity. Follow-
ng PCI, the median angina class improved from 3.0 (IQR:
.0 to 4.0) to 0.0 (IQR: 0.0 to 1.0; p  0.001 vs. baseline)
ith 71.1% of patients being angina free. After CABG, the
ngina classification improved from 2.0 (IQR: 2.0 to 4.0) to
.0 (IQR: 0.0 to 1.0; p  0.001 vs. baseline; p  0.67 vs.
CI), and 66.3% of patients were free from angina (p 
.33 vs. PCI).
iscussion
his multicenter trial failed to show that sirolimus-eluting
tenting is noninferior to CABG using predominantly
rterial grafts at mid-term follow-up for patients with ULM
isease. This was mainly caused by the higher rate of repeat
evascularization, whereas for the end points death and
yocardial infarction, the noninferiority criterion would
ave been reached. However, fewer periprocedural adverse
vents occurred in the PCI group, possibly due to its less
nvasive approach. In addition, the relief of symptoms
uring follow-up was similar between both reperfusion
egimens.
omparison with other studies. Recently published reg-
stries comparing drug-eluting stenting and CABG con-
rmed that treatment of ULM disease with PCI results in
ower or similar rates of cardiovascular events at mid- to
ong-term follow-up (9,10,20,21). In a relatively small
andomized study that did not use drug-eluting stents and
rterial bypass grafts consistently, there was an improvement
n left ventricular function in the PCI group, with fewer
linical adverse events (12). An important adverse prognos-
ic factor in interventional treatment is location in the distal
art of the ULM, as this requires more complex interven-
ional techniques (22). Recently, the randomized SYNTAX
rial of drug-eluting stenting versus CABG for ULMFigure 2 Kaplan-Meier Curves at Long-Term Follow-Up for the
Primary End Point and Its Components
(A) Kaplan-Meier curve for the primary combined clinical end point. (B) Kaplan-
Meier curve for acute myocardial infarction and death. (C) Kaplan-Meier
curve for repeat revascularization. The log-rank test was used for the com-
parison between sirolimus-eluting stenting and CABG. Abbreviations as in
Figure 1.
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Stenting Versus Surgery in Left Main Disease February 1, 2011:538–45tenosis and triple-vessel disease reported similar major
dverse cardiac and cerebrovascular event rates (13.7%
ABG vs. 15.8% PCI; p  0.44) at 12-month follow-up
or the ULM disease subgroup (11). Repeat revasculariza-
ion rates for ULM patients were similar to the current trial,
ith 11.8% after PCI in comparison to 6.5% after CABG
11). Cerebrovascular events were included in the primary
nd point in the SYNTAX trial. However, adding cerebro-
ascular events to the current trial would also have led to
ailure in meeting the criteria of noninferiority (p  0.11 for
oninferiority). Similar to the SYNTAX trial, patients not
ligible for the current study were entered into a prospective
egistry. In the current trial, the percentage of noneligible
atients was similar to the SYNTAX trial (56% vs. 58%)
ue to the pre-defined exclusion criteria. In contrast to the
YNTAX trial, noneligible registry patients undergoing
CI or surgery had worse clinical outcome at 12 months,
hich reflects the increased comorbidities and complexity of
isease.
In addition to the components of the primary end point,
e assessed adverse periprocedural events. These occurred
ignificantly more often after the more invasive CABG
pproach. These adverse events might have prognostic
mpact and are therefore used to compare different surgical
evascularization techniques (23,24).
estenosis. The issue of restenosis after stenting has been
artially addressed by the use of drug-eluting stents. How-
ver, as also shown in this trial, increased repeat revascular-
zation after PCI remains an ongoing problem and was the
ain factor for noninferiority failure when compared with
ABG. All restenoses were observed in patients with distal
LM disease, similar to results from other registries and
andomized clinical trials. Such studies have revealed a
arget vessel revascularization rate ranging from 2% to 38%,
epending on the percentage of patients with distal ULM
isease (7,9,10,20–22,25). In contrast, the rate of repeat
evascularization after CABG is usually in the range of 2%
o 6%, similar to the current trial (9–11,20,21). At first
lance, the high rate of occluded grafts and the much lower
evascularization rate might be difficult to interpret. How-
ver, many previous CABG trials have shown similar rates
f patients with occluded bypass grafts who do not have any
ymptoms and where no ischemia can be detected (26).
ince there was no routine repeat coronary angiography in
he SYNTAX trial, the rate of occluded bypass grafts cannot
e estimated (11). It is worthwhile mentioning the 65% rate
f total arterial revascularization achieved in CABG pa-
ients in the current study, a proportion that is significantly
igher than that was observed in other recent clinical trials
12). The increased arterial revascularization rate may lead
o improved patient outcomes during longer follow-up.
Stent thrombosis is a potentially important limitation of
rug-eluting stents with impaired endothelialization and
ealing (27). This is particularly important if several drug-
luting stents are used with overlapping of the struts,
esulting in increased drug dosages with subsequent im- haired re-endothelialization (28). Whereas stent restenosis
s usually associated with a relatively benign clinical out-
ome, stent thrombosis is associated with an increased risk
f myocardial infarction of up to 70% and an increased risk
f mortality of up to 45% (29,30). These findings necessitate
rolonged dual antiplatelet medication with aspirin and
lopidogrel for at least 12 months after drug-eluting stent
mplantation (31). In the current trial, no stent thrombosis
as observed.
ortality and infarction. The mortality and recurrent
nfarction rate in the CABG group was similar to the rate
bserved in previous trials, with in-hospital mortality rates
f approximately 1% to 5% and long-term mortality rates of
% to 15% (32–34). In contrast, early periprocedural mor-
ality was 0 in the current PCI group.
tudy limitations. The modest sample size and the lack of
onger-term follow-up are limitations of the current study.
he benefits of CABG compared with medical therapy
merged beyond 1 year in previous trials when perioperative
ortality and morbidity in the CABG group become offset
y mortality from coronary artery disease in the medical
roup (1–4). Hence, the apparent lack of difference of
ortality and reinfarction at 1 year is not completely
eassuring and does not contradict previously observed
onger-term benefits of CABG. However, large observa-
ional studies have not shown any major difference at
onger-term follow-up between CABG and PCI with
espect to mortality and myocardial infarction (10,35). In
ddition, the longer follow-up of 36.5 months in the current
tudy did not show a difference in comparison to the
2-month data. Another caveat is that the results were
btained only at highly experienced tertiary centers, which
ight preclude generalization, and also that stroke was not
ncluded in the combined clinical end point.
onclusions
CI with sirolimus-eluting stents is inferior to CABG at
2-month follow-up with respect to freedom from major
dverse cardiac events in patients with ULM stenosis.
nferiority is mainly driven by the higher repeat revascular-
zation rate, whereas death and myocardial infarction rates
eem to be noninferior in PCI patients at lower periopera-
ive morbidity. In highly experienced centers, the decision-
aking process on how to treat ULM disease should
herefore be based on an interdisciplinary approach taking
nto account the individual success, periprocedural risk,
otential restenosis, and graft occlusion rate based on the
orphology of the underlying lesion and patient comorbidi-
ies.
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